From L-R: Rondo CEO Shelley Force Aldred and CSO Nathan Trinklein
A dynamic oncology duo team up on an I/O startup focused on next-gen solid tumor fighters
In the notoriously flighty biotech industry, longtime partnerships aren’t necessarily the norm. But a pair of oncology vets with a history of collaboration apparently likes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
